Matchmaking investors pick Biogen, Pfizer as fave Allergan deal partners

Carly Helfand Who should serial buyer Allergan pick up next? It's the question on the minds of many industry watchers–including Evercore ISI analyst Umer Raffat, who ...

CRO giant WuXi is going private in a $3.3B deal

Damian Garde WuXi PharmaTech, China's largest CRO, agreed to a $ 3.3 billion buyout deal that would take it off of Wall Street and into the hands of some private investors. FierceBiotech ...

Boehringer takes a neuroscience approach to obesity with latest deal

Damian Garde Boehringer Ingelheim is pairing up with a small California biotech to explore the role circuits in the nervous system play in obesity, scouting for drug targets that could ...

Apogenix inks cancer drug development deal for China

John Carroll Germany's Apogenix, which is backed by SAP co-founder Dietmar Hopp, has struck an exclusive licensing agreement with CANbridge Life Sciences to develop and commercialize ...

Maryland Rep joins chorus of Amphastar critics, urging OD drug price deal

Tracy Staton Amphastar is in hot water with U.S. officials again. After New York and other states put the squeeze on the company to drop the price of its overdose drug, naloxone, Rep. ...

Novo Nordisk backs out of a diabetes deal with Zosano

Damian Garde Novo Nordisk has terminated a collaboration deal with Zosano Pharma, walking away from an agreement that would have paired its late-stage diabetes drug with the latter ...

UPDATED: Celgene pays $1B in landmark deal to buy into Juno’s pipeline of CAR-T drugs

John Carroll Celgene is paying about $ 1 billion to move to the front of the hectic race to build new CAR-T cancer therapies. The Big Biotech is shelling out $ 150 million upfront ...

Novartis nixes another $600M buyout deal for Gamida Cell

John Carroll Novartis won't be pulling the trigger on a $ 600 million buyout deal for Israel's Gamida Cell after all. Elbit Imaging, the majority owner of a minority stakeholder ...

ArGEN-X pairs up with Leo Pharma in a $116M dermatology deal

Damian Garde The antibody experts at arGEN-X have teamed up with dermatology-focused biotech Leo Pharma on a treatment for inflammatory skin diseases, inking a deal worth up to $ 116 ...

Pfizer continues its deal spree with a $600M option pact to buy AM-Pharma

John Carroll Continuing a deal spree aimed at beefing up a weak pipeline, Pfizer has agreed to pay $ 87.5 million for a stake in the Dutch biotech AM-Pharma along with an option to ...

Argos gets a $40M China deal for AGS-003

John Carroll China's Lummy HK and the China BioPharma Capital I Fund have agreed to acquire $ 10 million worth of Durham, NC-based Argos Therapeutics stock in exchange for rights ...

Flexus founders regroup after $1.25B Bristol-Myers deal

Damian Garde Flexus Biosciences turned heads around the industry when Bristol-Myers Squibb signed a $ 1.25 billion deal to buy the fledgling biotech in February, but the company's ...
Page 3 of 1612345...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS